Biosimilar Antibodies are antibodies sharing identical active biological components with the original therapeutic antibodies, serving as positive controls for drug efficacy evaluation in scientific research and supporting functional validation of target proteins.
Enokizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL9, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. A humanized immunoglobulin G1k anti-interleukin-9 mAb.
Guselkumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL23A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation 2. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Pateclizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting LTA/TNFSF1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
OST 577 is a monoclonal antibody biosimilar expressed in CHO cells, targeting Hepatitis B Virus (HBV), for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Edrecolomab is a monoclonal antibody biosimilar expressed in CHO cells, targeting EPCAM, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Dacetuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD40, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Dusigitumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IGF1/IGF2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Detumomab is a Humanized Monoclonal antibody, expressed in Mammalian cells.
This product is for research use only (RUO) by laboratories. It is not suitable for use in humans or as a medicine. Anivovetmab is a Chimeric Monoclonal antibody targeting Capsid protein VP2, expressed in Mammalian cells.
Meplazumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD147, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Meplazumab is a humanized anti-CD147 antibody that can competitively inhibit the binding of SP and CD147, prevent viruses from invading host cells, and provide a potential target for the development of antiviral drugs.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Suppliers
Request a product
Please provide the required information below so that we can quickly source your products.
